February 11, 2014 (Shareholders Foundation) - An investigation on behalf of investors of Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) shares was initiated over potential securities laws violations by Oramed Pharmaceuticals and certain of its directors and officers in connection certain financial statements.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) concerning whether a series of statements by Oramed Pharmaceuticals, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Oramed Pharmaceuticals, Inc. reported that its Net Loss increased from $3.34 million in 2012 to $4.23 million in 2013.

Shares of Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) grew from $7.15 per share on December 19, 2013 to as high as $28.91 per share on January 10, 2014.

Then on February 3, 2014, a report was published questioning the integrity and robustness of the data presented by the Company regarding its Oral Insulin Pill, with the report calling such data 'Completely Worthless'.

Shares of Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) declined on February 4, 2014 to as low as $14.62 per share.

On February 11, 2014, NASDAQ:ORMP shares closed at $14.88 per share.